STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
85
13F, latest reported quarter
Conversions, 180 days
24
Codes C/M, not in net · no price filed
What the filings say about BLND
Insiders, 180 days
+$11.6M net bought
5 buyers · 4 sellers · 70% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$341.5K
10 notices
Blend Labs insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Blend Labs, Inc. insiders bought a net $11.6M of stock across 177 Form 4 purchases and sales, with 5 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
26 earlier Form 4 trades (code P or S) here by this insider (26 sales), the last on Sep 28, 2026.
The trade is 0.3% of the 7,803,566 shares held after it.
1 other insider sold within 30 days.
85 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: HEAD OF BLEND Ghamsari Nima sold about $24.7K of BLND under a 10b5-1 plan on Oct 5, 2026; 1 other insider sold within 30 days and 85 funds added in the latest 13F quarter.
25 earlier Form 4 trades (code P or S) here by this insider (25 sales), the last on Sep 21, 2026.
The trade is 0.3% of the 7,827,838 shares held after it.
1 other insider sold within 30 days.
85 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: HEAD OF BLEND Ghamsari Nima sold about $24.8K of BLND under a 10b5-1 plan on Sep 28, 2026; 1 other insider sold within 30 days and 85 funds added in the latest 13F quarter.
24 earlier Form 4 trades (code P or S) here by this insider (24 sales), the last on Sep 14, 2026.
The trade is 0.3% of the 7,850,361 shares held after it.
1 other insider sold within 30 days.
85 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: HEAD OF BLEND Ghamsari Nima sold about $25.0K of BLND under a 10b5-1 plan on Sep 21, 2026; 1 other insider sold within 30 days and 85 funds added in the latest 13F quarter.
177 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Nobody has filed for crossing 5%. That is a fact, not missing data.
BLND planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Ghamsari Nima
Filed 2026-10-26
$23.9K
Ghamsari Nima
Filed 2026-10-19
$25.7K
Ghamsari Nima
Filed 2026-10-13
$24.5K
Ghamsari Nima
Filed 2026-10-05
$24.6K
Ghamsari Nima
Filed 2026-09-28
$24.8K
BLND mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
State Street(R) SPDR(R) S&P(R) Software & Services ETF
$3.0M position · as of 2026-06-30
0.8%
1290 Essex Small Cap Growth Fund
$847.4K position · as of 2026-07-31
0.7%
PACE Small/Medium Co Growth Equity Investments
$340.4K position · as of 2026-07-31
0.1%
Global X FinTech ETF
$158.7K position · as of 2026-05-31
0.1%
iShares Micro-Cap ETF
$1.0M position · as of 2026-06-30
0.1%
Goldman Sachs ActiveBeta(R) U.S. Small Cap Equity ETF
$513.5K position · as of 2026-05-31
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
5 insiders reported buying shares.
The record shows a net $11.6M bought by insiders over 180 days, 85 funds added last quarter, $341.5K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Revenue, TTM BLND
FY Dec 2025
n/a
FY Dec 2024
$162.0M
FY Dec 2023
$156.8M
FY Dec 2022
$235.2M
FY Dec 2021
$234.5M
Jun 2026
$33.8M
Mar 2026
$30.8M
Dec 2025
$31.6M
Sep 2025
$32.9M
Jun 2025
$31.6M
Mar 2025
$26.8M
Dec 2024
$41.4M
Sep 2024
$45.2M
At each fiscal year end
Single quarter
Net margin, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Net margin, TTM BLND
FY Dec 2025
n/a
FY Dec 2024
-26.8%
FY Dec 2023
-113.9%
FY Dec 2022
-306.2%
FY Dec 2021
-72.5%
Jun 2026
-4.4%
Mar 2026
-26.1%
Dec 2025
-21.6%
Sep 2025
+36.8%
Jun 2025
-21.6%
Mar 2025
-35.5%
Dec 2024
-2.0%
Sep 2024
-5.4%
At each fiscal year end
Single quarter
Free cash flow, TTM
$7.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM BLND
FY Dec 2025
-$81.0K
FY Dec 2024
-$22.8M
FY Dec 2023
-$127.7M
FY Dec 2022
-$192.5M
FY Dec 2021
-$129.2M
Jun 2026
$7.1M
Mar 2026
$6.2M
Dec 2025
-$21.0K
Sep 2025
-$5.8M
Jun 2025
-$10.1M
Mar 2025
$15.8M
Dec 2024
-$7.1M
Sep 2024
-$1.4M
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity BLND
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
1.76x
FY Dec 2021
0.28x
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt BLND
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
-0.92x
FY Dec 2022
-0.88x
FY Dec 2021
-0.60x
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on equity BLND
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
-343.9%
FY Dec 2022
-160.4%
FY Dec 2021
-36.2%
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on assets BLND
FY Dec 2025
n/a
FY Dec 2024
-22.6%
FY Dec 2023
-55.9%
FY Dec 2022
-93.2%
FY Dec 2021
-25.6%
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
-2.7%
Jun 2025
-10.7%
Mar 2025
-16.5%
Dec 2024
-22.6%
Sep 2024
-28.9%
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on invested capital BLND
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on capital employed BLND
FY Dec 2025
n/a
FY Dec 2024
-31.2%
FY Dec 2023
-50.2%
FY Dec 2022
-102.9%
FY Dec 2021
-32.0%
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
-15.1%
Jun 2025
-20.0%
Mar 2025
-24.6%
Dec 2024
-31.2%
Sep 2024
-26.0%
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing BLND
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no share count filed
Enterprise value BLND
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
no share count filed
FCF yield BLND
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing BLND
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
BLND ranks highest on insider conviction (98th percentile) and risk and compliance (70th), and lowest on growth (32nd), among Software & IT peers.
Growth
32
Inputs
Revenue growth, YoY+6.8% · 44 pct, sector of 480
Backlog growth, YoY-11.5% · 19 pct, sector of 182
Insider conviction
98
Inputs
Net Form 4 buying (codes P and S), 180d$11.8M · 98 pct, sector of 284
Insider buyers, 180d5 · 98 pct, sector of 290
Institutional and government
48
Inputs
Funds adding, latest quarter85 · 48 pct, sector of 415
Congress net buyers, 365dno Congress trades in 365 days
Federal contracts, 180dno federal contracts in 180 days
Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
70
Inputs
Short interest, % of float+5.1% · 50 pct, sector of 528
Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
New text in Risk Factors, latest 10-K+4.2% · 90 pct, sector of 316
3 not measured: Profitability, Financial health, US patents
Profitability needs 2 of 4 inputs, 0 present: the filed year and its quarters do not reconcile, so the trailing figure is withheld
Financial health needs 1 of 2 inputs, 0 present: equity is zero or negative, the ratio has no meaning; no debt to cover
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
BLND filings, in plain words
Are Blend Labs insiders buying or selling BLND?
In the 180 days to 2026-10-28, Blend Labs insiders were net buyers, a net $11.6M: $11.9M of purchases and $326.4K of sales reported on Form 4, by 5 buyers and 4 sellers.
Are there planned insider sales of BLND?
Yes. 10 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $341.5K of stock; the latest, by Ghamsari Nima, was filed 2026-10-26.
Read the full summary
In the 180 days to 2026-10-28, Blend Labs insiders were net buyers of BLND, a net $11.6M across purchases and sales reported on Form 4 by 5 buyers and 4 sellers. Most of that figure, $11.9M, came from a holder of 10% or more rather than an officer or director. Purchases outweighed sales more than tenfold by value. 5 insiders reported purchases in that window. 70% of the 10 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 10 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $341.5K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address, your watchlist and your preferences, nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in and remember this choice.
Google Analytics 4 and Microsoft Clarity load only if you allow them here; they
count visits and record how pages are used. We run no advertising and never sell
data. Details in the privacy policy. Change this any time
via "Cookie settings" in the footer.